Lilly’s EBGLYSS Reinforces Long-Term Disease Control in Atopic Dermatitis

Eli Lilly and Company reported new long-term data showing that EBGLYSS delivers sustained efficacy in patients with atopic dermatitis for up to four years. The findings, presented at the American Academy of Dermatology Annual Meeting, are based on the ongoing Phase 3b ADlong open-label extension study and highlight the potential of EBGLYSS to provide long-term disease control with a convenient once-monthly maintenance regimen.

In the ADlong study (NCT05916365), patients receiving continuous EBGLYSS treatment achieved consistently high levels of skin clearance and itch relief over time. At up to four years, 94% of patients achieved EASI-75, while 75% reached EASI-90, indicating near-complete skin clearance. Additionally, 68% of patients achieved Investigator’s Global Assessment (IGA) scores of 0 or 1, reflecting clear or almost clear skin, and 78% reported meaningful itch reduction with a Pruritus Numeric Rating Scale score of 4 or less. These outcomes were sustained in most patients with once-monthly dosing, with 80% maintaining response on the maintenance regimen. Notably, 77% of patients were treated with EBGLYSS as monotherapy, and 80% achieved these results without the use of topical corticosteroids.

These long-term findings build on earlier Phase 3 results reported in March 2026, which demonstrated EBGLYSS efficacy in pediatric patients and supported potential label expansion

Safety findings from the first year of the ADlong study were consistent with the known safety profile of EBGLYSS, with no new safety signals observed. Most adverse events were mild to moderate and rarely led to discontinuation. The most commonly reported treatment-related adverse events included conjunctivitis (6.9%) and injection-site reactions (0.6%). A post-hoc analysis further showed that patients receiving monthly EBGLYSS monotherapy experienced less than one flare per year, supporting its role in long-term disease control.

EBGLYSS is a monoclonal antibody that selectively inhibits interleukin-13 (IL-13), a key cytokine driving type-2 inflammation in atopic dermatitis. By targeting IL-13 signaling, the therapy helps reduce inflammation, improve skin barrier function, and alleviate persistent itch.

According to Emma Guttman-Yassky, these findings reinforce the potential of EBGLYSS to provide durable disease control and reduce unpredictable flares in patients with moderate-to-severe disease.

EBGLYSS is already approved in the United States, Japan, and Canada (2024), and in the European Union (2023), and is positioned as a first-line biologic treatment option with the flexibility of monotherapy and once-monthly maintenance dosing for patients aged 12 years and older who are not adequately controlled on topical therapies.

Its clinical development program in atopic dermatitis includes seven global studies involving more than 1,600 patients, spanning monotherapy trials (ADvocate 1 and 2), combination therapy (ADhere), long-term extension (ADjoin), as well as adolescent and pediatric studies (ADore and ADorable 1 and 2). Beyond atopic dermatitis, EBGLYSS is also being investigated in other type-2 inflammatory conditions, including allergic rhinitis and chronic rhinosinusitis with nasal polyps, reflecting its broader potential in immunology.

References

Lilly’s EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis, 27 March 2026, Lilly’s EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis | Eli Lilly and Company

Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis (ADlong), ClinicalTrials.gov ID NCT05916365, https://clinicaltrials.gov/study/NCT05916365